IP Library Granted Patent US 7,074,407
Granted Patent B1
US 7,074,407 · App. 09/523,033 · Granted Jul 11, 2006

Method for increasing HDL cholesterol level

Assignee: Avant Immunotherapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,074,407
App. No.
09/523,033
Granted
Jul 11, 2006
Kind
B1
Abstract

The present invention provides a method for increasing HDL cholesterol in a mammal by stimulating an immune response that inhibits the function of CETP. Such an immune response can be induced by immunizing with CETP or fragments of CETP (together termed “CETP Peptides”) which contain an epitope capable of stimulating such a response. The peptides can be conjugated to a carrier, such as KLH or ovalbumin, in order to increase immunogenicity. Adjuvants can also be administered.

Claims (8)

1. A method of inducing an immune response that increases HDL cholesterol levels in a mammal exhibiting or at risk of exhibiting low levels of serum HDL cholesterol comprising administering to said mammal an immunogenic composition comprising a full-length cholesteryl ester transfer protein (CETP) and further comprising a carrier linked to said protein and wherein said immunogenic composition is capable of raising antibodies that recognize said mammal's endogenous CETP.

2. The method of claim 1 , wherein said carrier is selected from the group consisting of keyhole limpet hemocyanin (KLH), ovalbumin, and Diptheria toxoid.

3. The method of claim 1 or 2 , wherein said composition is administered with an adjuvant.

4. The method of claim 1 , wherein said administration is repeated.

5. The method of 1 , wherein said full-length CETP is the native CETP of said mammal.

6. The method of claim 1 , wherein said full-length CETP is a human CETP.

7. The method of claim 1 , wherein said full-length CETP is a rabbit CETP.

8. The method of claim 1 , wherein said full-length CETP differs from the native CETP of said mammal.

Assignments (2)
CHANGE OF NAME Recorded Mar 9, 2009
From: AVANT IMMUNOTHERAPEUTICS, INC. (NEEDHAM, MASSACHUSETTS)
To: CELLDEX THERAPEUTICS, INC.
Reel/Frame 022380/0239 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 21, 2001
From: THE IMMUNE RESPONSE CORPORATION
To: AVANT IMMUNOTHERAPEUTICS, INC.
Reel/Frame 011985/0567 →
Continuity (1)
Continuation 0848245400 · Jun 6, 1995